009 Performance of a Mobile Single-Lead Electrocardiogram Technology for Atrial Fibrillation Screening in a Semi-Rural African Population: Insights from the Australian Led TEFF-AF Study

Pitman, Bradley M.; Chew, Sok-Hui; Wong, Christopher X.; Jaghoori, Amenah; Iwai, Shinsuke; Chew, Andrew; Sanders, Prashanthan; Lau, Dennis H.

doi:10.1016/j.hlc.2020.09.016

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hardware and software advancements have led to the development of novel devices, which are both practical and aff ordable, and enable monitoring of vulnerable populations from the comfort of their homes, while at the same time providing critical alerts for events requiring prompt medical attention or hospitalization [3]. Some devices have demonstrated new ways of monitoring, from adhesive patches to mobile telemetry and both have shown good feasibility as monitoring tools [4,5]. Wearable technology is a new concept for noninvasive monitoring of vital signs based on adapted sensors to the body surface.…”

Section: Introductionmentioning

confidence: 99%

Initial Clinical Experience with New Technology ePatchTM Extended Holter Monitoring

Blanch,

Ortega,

Escura

et al. 2024

J Biomed Res Environ Sci

View full text Add to dashboard Cite

Introduction and objectives: Conventional methods of Holter (H) monitoring, data analysis and reporting can be inefficient, leading to high costs and long response times. Traditional H devices can be cumbersome to wear, and uncomfortable testing can reduce patient compliance and satisfaction, impacting diagnostic performance. This new device ePatchTM is a simple application of patch and activation without the need to charge the battery and without connecting cables (Figure 1). Up to 14 days of continuous Electrocardiogram (ECG) recording. It can be worn in the shower and during exercise. Single channel, up to 14 days. Two channels, up to 7 days. Our objective is to evaluate the quality and diagnostic efficacy of ePatchTM in different clinical settings. Methods: Prospective study of patients with ePatchTM placed in our centre requested for the study of undocumented palpitations, syncope or cryptogenic stroke. Clinical variables, diagnostic accuracy and time to diagnostic event are analysed. Results: The first 154 patients were included, of whom (51.3%) were women, with a mean age of 66.6 years (range 18 to 89). The most frequent indication was palpitations (37%) followed by cryptogenic stroke (34.4%), followed by syncope (28.5%). All patients had correct compliance and tolerance and the monitored ECG was of good quality. A conclusive diagnosis: (sustained symptomatic tachyarrhythmia, atrioventricular block with bradyarrhythmia, significant pauses or atrial fibrillation) was obtained in 15 patients (9.7% of the total). 14-, 7-, and 5-day recorders were used. The median event time since ePatchTM logging began was 2.6 days (range 1 to 5 days). Only the duration of H (OR 10.6), and left atrial dilation (OR 5) were significant predictors of arrhythmic event in the multivariate analysis. Conclusion: ePatchTM is a new H device that offers a simple, complete and effective ECG monitoring system. This new technology is safe and has numerous advantages: spending less time on device logistics and handling, preparing patients efficiently, eliminating the need for additional consumables, and constantly replacing the battery. The ECG monitor can be used for up to 14 days. It is designed to address the challenges of traditional H monitoring.

show abstract

Section: Introductionmentioning

confidence: 99%